# Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial

> **NCT05804656** · PHASE3 · COMPLETED · sponsor: **CKD Bio Corporation** · enrollment: 300 (actual)

## Conditions studied

- Glabellar Lines

## Interventions

- **DRUG:** CKDB-501A
- **DRUG:** Botox®

## Key facts

- **NCT ID:** NCT05804656
- **Lead sponsor:** CKD Bio Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-13
- **Primary completion:** 2023-08-29
- **Final completion:** 2023-11-20
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05804656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05804656, "Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05804656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*